Advanced Researchs of Autoimmune Thyroid Disorder Complicated with Differentiated Thyroid Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 CHENGTing ,  DAIWen-jie , MAWei-chang , ZHAOBao-guo

Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China;

Corresponding author：

DAIWen-jie, Email: davidhmu@163.com

Keywords：

Autoimmune thyroid diseases; Hashimoto disease; Differentiated thyroid carcinoma

DOI：

10.7507/1007-9424.20140282

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the advanced researchs of autoimmune thyroid disease(ATD) complicated with differentiated thyroid cancer (DTC). Methods The related literatures about concurrent ATD and DTC were consulted and reviewed. Results Hashimoto diseas (HD) complicated with DTC at home and abroad were reported more and more, whether merging with HD or other ATD disease could affect the prognosis of papillary thyroid cancer (PTC) was a controversial topic. HD and DTC (mainly PTC) had some same epidemiological and molecular features. Conclusion Better understanding of clinical pathology and characteristic of DTC concurrent with ATD can provide some new insights to immunotherapy for DTC.

Citation： CHENGTing, DAIWen-jie, MAWei-chang, ZHAOBao-guo. Advanced Researchs of Autoimmune Thyroid Disorder Complicated with Differentiated Thyroid Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(9): 1179-1183. doi: 10.7507/1007-9424.20140282 Copy

1.	Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973-2002[J]. Cancer Causes Control, 2009, 20(5):525-531.
2.	Pellegriti G, De Vathaire F, Scollo C, et al. Papillary thyroid cancer incidence in the volcanic area of Sicily[J]. J Natl Cancer Inst, 2009, 101(22):1575-1583.
3.	Renehan AG, Soerjomataram I, Tyson M, et al. Incident cancer burden attributable to excess body mass index in 30 European countries[J]. Int J Cancer, 2010, 126(3):692-702.
4.	Karch A, Thomas SL. Autoimmune thyroiditis as a risk factor for stroke:a historical cohort study[J]. Neurology, 2014, 82(18):1643-1652.
5.	de Matos PS, Ferreira AP, Ward LS. Prevalence of papillary microcarcinoma of the thyroid in Brazilian autopsy and surgical series[J]. Endocr Pathol, 2006, 17(2):165-173.
6.	陆再英, 钟南山.内科学[M].第7版.北京:人民卫生出版社, 2008:712-727.
7.	Pacifico F, Leonardi A. Role of NF-kappaB in thyroid cancer[J]. Mol Cell Endocrinol, 2010, 321(1):29-35.
8.	Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland[J]. AMA Arch Surg, 1955, 70(2):291-297.
9.	Boyd CM, Baker JR Jr. The immunology of thyroid cancer[J]. Endocrinol Metab Clin North Am, 1996, 25(1):159-179.
10.	高恩君, 张伟辉.桥本氏甲状腺炎合并甲状腺癌的研究进展[J].现代生物医学进展, 2013, 13(18):3594-3596, 3530.
11.	Zosin I, Golu I, Cornianu M, et al. Some clinical aspects in chronic autoimmune thyroiditis associated with thyroid differentiated cancer[J]. Maedica (Buchar), 2012, 7(4):277-283.
12.	严丽, 李情怀, 王树峰, 等.术前TSH水平与甲状腺结节良恶性关系[J].中国普通外科杂志, 2012, 21(11):1373-1376.
13.	Ye ZQ, Gu DN, Hu HY, et al. Hashimoto's thyroiditis, microcalcification and raised thyrotropin levels within normal range are associated with thyroid cancer[J]. World J Surg Oncol, 2013, 11:56.
14.	Zhang L, Li H, Ji QH, et al. The clinical features of papillary thyroid cancer in Hashimoto's thyroiditis patients from an area with a high prevalence of Hashimoto's disease[J]. BMC Cancer, 2012, 12:610.
15.	Fiore E, Rago T, Latrofa F, et al. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma:role of TSH and of treatment with L-thyroxine[J]. Endocr Relat Cancer, 2011, 18(4):429-437.
16.	Konturek A, Barczyński M, Wierzchowski W, et al. Coexistence of papillary thyroid cancer with Hashimoto thyroiditis[J]. Langenbecks Arch Surg, 2013, 398(3):389-394.
17.	Gul K, Dirikoc A, Kiyak G, et al. The association between thyroid carcinoma and hashimoto's thyroiditis:the ultrasonographic and histopathologic characteristics of malignant nodules[J]. Thyroid, 2010, 20(8):873-878.
18.	Matesa-Anić D, Matesa N, Dabelić N, et al. Coexistence of papillary carcinoma and Hashimoto's thyroiditis[J]. Acta Clin Croat, 2009, 48(1):9-12.
19.	Yoon YH, Kim HJ, Lee JW, et al. The clinicopathologic differences in papillary thyroid carcinoma with or without co-existing chronic lymphocytic thyroiditis[J]. Eur Arch Otorhinolaryngol, 2012, 269(3):1013-1017.
20.	Paulson LM, Shindo ML, Schuff KG. Role of chronic lymphocytic thyroiditis in central node metastasis of papillary thyroid carcinoma[J]. Otolaryngol Head Neck Surg, 2012, 147(3):444-449.
21.	Repplinger D, Bargren A, Zhang YW, et al. Is hashimoto's thyroiditis a risk factor for papillary thyroid cancer?[J]. J Surg Res, 2008, 150(1):49-52.
22.	Loh KC, Greenspan FS, Dong F, et al. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma[J]. J Clin Endocrinol Metab, 1999, 84(2):458-463.
23.	Boi F, Lai ML, Marziani B, et al. High prevalence of suspicious cytology in thyroid nodules associated with positive thyroid autoantibodies[J]. Eur J Endocrinol, 2005, 153(5):637-642.
24.	Souza SL, Montalli Da Assumpção LV, Ward LS. Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer[J]. Thyroid, 2003, 13(5):491-495.
25.	Muzza M, Degl'innocenti D, Colombo C, et al. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation:clinical and molecular studies[J]. Clin Endocrinol (Oxf), 2010, 72(5):702-708.
26.	Shacter E, Weitzman SA. Chronic inflammation and cancer[J]. Oncology, 2002, 16(2):217-230.
27.	Campos LA, Picado SM, Guimarães AV, et al. Thyroid papillary carcinoma associated to Hashimoto's thyroiditis[J]. Braz J Otorhinolaryngol, 2012, 78(6):77-80.
28.	Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis[J]. Endocrinology, 2007, 148(3):936-941.
29.	Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC[J]. Oncogene, 2003, 22(29):4578-4580.
30.	Zafon C, Obiols G. The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice[J]. Endocrinol Nutr, 2009, 56(4):176-186.
31.	Xing M. BRAF mutation in thyroid cancer[J]. Endocr Relat Cancer, 2005, 12(2):245-262.
32.	Kim YS, Kim JS, Bae JS, et al. Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma[J]. World J Surg Oncol, 2013, 11:99.
33.	Arif S, Blanes A, Diaz-Cano SJ. Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma[J]. Histopathology, 2002, 41(4):357-362.
34.	Kang DY, Kim KH, Kim JM, et al. High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population[J]. Thyroid, 2007, 17(11):1031-1038.
35.	Guarino V, Castellone MD, Avilla EA. Thyroid cancer and inflammation[J]. Mol Cell Endocrinol, 2010, 321(1):94-102.
36.	Fischer AH, Bond JA, Taysavang P, et al. Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure[J]. Am J Pathol, 1998, 153(5):1443-1450.
37.	Stassi G, Todaro M, Zerilli M, et al. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10[J]. Cancer Res, 2003, 63(20):6784-6790.
38.	Cunha LL, Tincani AJ, Assumpção LV, et al. Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiatedthyroid cancer[J]. Clinics (Sao Paulo), 2011, 66(7):1203-1208.
39.	Kim YS, Choi HJ, Kim ES. Papillary thyroid carcinoma with thyroiditis:lymph node metastasis, complications[J]. J Korean Surg Soc, 2013, 85(1):20-24.
40.	Sakorafas GH, Giotakis J, Stafya V. Papillary thyroid microcarcinoma:a surgical perspective[J]. Cancer Treat Rev, 2005, 31(6):423-438.
41.	Kim HS, Choi YJ, Yun JS. Features of papillary thyroid microcarcinoma in the presence and absence of lymphocytic thyroiditis[J]. Endocr Pathol, 2010, 21(3):149-153.
42.	Kebebew E, Treseler PA, Ituarte PH, et al. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited[J]. World J Surg, 2001, 25(5):632-627.
43.	Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF (V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis[J]. Thyroid, 2009, 19(2):137-141.
44.	Singh B, Shaha AR, Trivedi H, et al. Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma:impact on presentation, management, and outcome[J]. Surgery, 1999, 126(6):1070-1076.
45.	Yano Y, Shibuya H, Kitagawa W, et al. Recent outcome of Graves' disease patients with papillary thyroid cancer[J]. Eur J Endocrinol, 2007, 157(3):325-329.
46.	Papewalis C, Ehlers M, Schott M. Advances in cellular therapy for the treatment of thyroid cancer[J]. J Oncol, 2010, 2010:179491.
47.	Kim S, Prichard CN, Younes MN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice[J]. Clin Cancer Res, 2006, 12(2):600-607.
48.	Papewalis C, Wuttke M, Jacobs B, et al. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma[J]. Horm Metab Res, 2008, 40(2):108-116.

1. Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973-2002[J]. Cancer Causes Control, 2009, 20(5):525-531.
2. Pellegriti G, De Vathaire F, Scollo C, et al. Papillary thyroid cancer incidence in the volcanic area of Sicily[J]. J Natl Cancer Inst, 2009, 101(22):1575-1583.
3. Renehan AG, Soerjomataram I, Tyson M, et al. Incident cancer burden attributable to excess body mass index in 30 European countries[J]. Int J Cancer, 2010, 126(3):692-702.
4. Karch A, Thomas SL. Autoimmune thyroiditis as a risk factor for stroke:a historical cohort study[J]. Neurology, 2014, 82(18):1643-1652.
5. de Matos PS, Ferreira AP, Ward LS. Prevalence of papillary microcarcinoma of the thyroid in Brazilian autopsy and surgical series[J]. Endocr Pathol, 2006, 17(2):165-173.
6. 陆再英, 钟南山.内科学[M].第7版.北京:人民卫生出版社, 2008:712-727.
7. Pacifico F, Leonardi A. Role of NF-kappaB in thyroid cancer[J]. Mol Cell Endocrinol, 2010, 321(1):29-35.
8. Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland[J]. AMA Arch Surg, 1955, 70(2):291-297.
9. Boyd CM, Baker JR Jr. The immunology of thyroid cancer[J]. Endocrinol Metab Clin North Am, 1996, 25(1):159-179.
10. 高恩君, 张伟辉.桥本氏甲状腺炎合并甲状腺癌的研究进展[J].现代生物医学进展, 2013, 13(18):3594-3596, 3530.
11. Zosin I, Golu I, Cornianu M, et al. Some clinical aspects in chronic autoimmune thyroiditis associated with thyroid differentiated cancer[J]. Maedica (Buchar), 2012, 7(4):277-283.
12. 严丽, 李情怀, 王树峰, 等.术前TSH水平与甲状腺结节良恶性关系[J].中国普通外科杂志, 2012, 21(11):1373-1376.
13. Ye ZQ, Gu DN, Hu HY, et al. Hashimoto's thyroiditis, microcalcification and raised thyrotropin levels within normal range are associated with thyroid cancer[J]. World J Surg Oncol, 2013, 11:56.
14. Zhang L, Li H, Ji QH, et al. The clinical features of papillary thyroid cancer in Hashimoto's thyroiditis patients from an area with a high prevalence of Hashimoto's disease[J]. BMC Cancer, 2012, 12:610.
15. Fiore E, Rago T, Latrofa F, et al. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma:role of TSH and of treatment with L-thyroxine[J]. Endocr Relat Cancer, 2011, 18(4):429-437.
16. Konturek A, Barczyński M, Wierzchowski W, et al. Coexistence of papillary thyroid cancer with Hashimoto thyroiditis[J]. Langenbecks Arch Surg, 2013, 398(3):389-394.
17. Gul K, Dirikoc A, Kiyak G, et al. The association between thyroid carcinoma and hashimoto's thyroiditis:the ultrasonographic and histopathologic characteristics of malignant nodules[J]. Thyroid, 2010, 20(8):873-878.
18. Matesa-Anić D, Matesa N, Dabelić N, et al. Coexistence of papillary carcinoma and Hashimoto's thyroiditis[J]. Acta Clin Croat, 2009, 48(1):9-12.
19. Yoon YH, Kim HJ, Lee JW, et al. The clinicopathologic differences in papillary thyroid carcinoma with or without co-existing chronic lymphocytic thyroiditis[J]. Eur Arch Otorhinolaryngol, 2012, 269(3):1013-1017.
20. Paulson LM, Shindo ML, Schuff KG. Role of chronic lymphocytic thyroiditis in central node metastasis of papillary thyroid carcinoma[J]. Otolaryngol Head Neck Surg, 2012, 147(3):444-449.
21. Repplinger D, Bargren A, Zhang YW, et al. Is hashimoto's thyroiditis a risk factor for papillary thyroid cancer?[J]. J Surg Res, 2008, 150(1):49-52.
22. Loh KC, Greenspan FS, Dong F, et al. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma[J]. J Clin Endocrinol Metab, 1999, 84(2):458-463.
23. Boi F, Lai ML, Marziani B, et al. High prevalence of suspicious cytology in thyroid nodules associated with positive thyroid autoantibodies[J]. Eur J Endocrinol, 2005, 153(5):637-642.
24. Souza SL, Montalli Da Assumpção LV, Ward LS. Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer[J]. Thyroid, 2003, 13(5):491-495.
25. Muzza M, Degl'innocenti D, Colombo C, et al. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation:clinical and molecular studies[J]. Clin Endocrinol (Oxf), 2010, 72(5):702-708.
26. Shacter E, Weitzman SA. Chronic inflammation and cancer[J]. Oncology, 2002, 16(2):217-230.
27. Campos LA, Picado SM, Guimarães AV, et al. Thyroid papillary carcinoma associated to Hashimoto's thyroiditis[J]. Braz J Otorhinolaryngol, 2012, 78(6):77-80.
28. Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis[J]. Endocrinology, 2007, 148(3):936-941.
29. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC[J]. Oncogene, 2003, 22(29):4578-4580.
30. Zafon C, Obiols G. The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice[J]. Endocrinol Nutr, 2009, 56(4):176-186.
31. Xing M. BRAF mutation in thyroid cancer[J]. Endocr Relat Cancer, 2005, 12(2):245-262.
32. Kim YS, Kim JS, Bae JS, et al. Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma[J]. World J Surg Oncol, 2013, 11:99.
33. Arif S, Blanes A, Diaz-Cano SJ. Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma[J]. Histopathology, 2002, 41(4):357-362.
34. Kang DY, Kim KH, Kim JM, et al. High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population[J]. Thyroid, 2007, 17(11):1031-1038.
35. Guarino V, Castellone MD, Avilla EA. Thyroid cancer and inflammation[J]. Mol Cell Endocrinol, 2010, 321(1):94-102.
36. Fischer AH, Bond JA, Taysavang P, et al. Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure[J]. Am J Pathol, 1998, 153(5):1443-1450.
37. Stassi G, Todaro M, Zerilli M, et al. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10[J]. Cancer Res, 2003, 63(20):6784-6790.
38. Cunha LL, Tincani AJ, Assumpção LV, et al. Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiatedthyroid cancer[J]. Clinics (Sao Paulo), 2011, 66(7):1203-1208.
39. Kim YS, Choi HJ, Kim ES. Papillary thyroid carcinoma with thyroiditis:lymph node metastasis, complications[J]. J Korean Surg Soc, 2013, 85(1):20-24.
40. Sakorafas GH, Giotakis J, Stafya V. Papillary thyroid microcarcinoma:a surgical perspective[J]. Cancer Treat Rev, 2005, 31(6):423-438.
41. Kim HS, Choi YJ, Yun JS. Features of papillary thyroid microcarcinoma in the presence and absence of lymphocytic thyroiditis[J]. Endocr Pathol, 2010, 21(3):149-153.
42. Kebebew E, Treseler PA, Ituarte PH, et al. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited[J]. World J Surg, 2001, 25(5):632-627.
43. Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF (V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis[J]. Thyroid, 2009, 19(2):137-141.
44. Singh B, Shaha AR, Trivedi H, et al. Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma:impact on presentation, management, and outcome[J]. Surgery, 1999, 126(6):1070-1076.
45. Yano Y, Shibuya H, Kitagawa W, et al. Recent outcome of Graves' disease patients with papillary thyroid cancer[J]. Eur J Endocrinol, 2007, 157(3):325-329.
46. Papewalis C, Ehlers M, Schott M. Advances in cellular therapy for the treatment of thyroid cancer[J]. J Oncol, 2010, 2010:179491.
47. Kim S, Prichard CN, Younes MN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice[J]. Clin Cancer Res, 2006, 12(2):600-607.
48. Papewalis C, Wuttke M, Jacobs B, et al. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma[J]. Horm Metab Res, 2008, 40(2):108-116.

Previous Article
Review of The Biological Significance of Transmembrane 4 Super Family in Digestive System Cancer
Next Article
甲状腺乳头状癌合并髓样癌1例报道

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Advanced Researchs of Autoimmune Thyroid Disorder Complicated with Differentiated Thyroid Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content